Ricardo L. A.
- Country
- Spain
- Department
- Oncology for pediatrics
Research Overview
- Phase I/II Evaluation of Sodium 2-Hydroxylinoleate in Pediatric Relapsed/Refractory Neuroblastoma and Solid Tumors, Alone and with Chemotherapy or Targeted Therapies
- Phase 3 Study of Busulfan, Melphalan, and Chemoimmunotherapy in High-Risk Neuroblastoma Patients with Insufficient Metastatic Response
- Evaluation of Irinotecan, Ifosfamide, Vincristine, and Dactinomycin in Frontline and Relapsed Rhabdomyosarcoma in Pediatric and Adult Populations
Data & Insights
Has run more than one trial at 121 of 253 partner sites.
Specializations
Pediatric Oncology
This investigator specializes in treating complex pediatric liver cancers, with particular focus on hepatoblastoma and hepatocellular carcinoma. Their expertise extends to various risk-stratified treatment approaches for these conditions.
- Liver tumor management strategies
- Risk-adapted therapeutic protocols
- Multi-modal treatment approaches
Neuroblastoma Treatment
The investigator has extensive experience in treating high-risk neuroblastoma and refractory neuroblastoma, implementing innovative therapeutic strategies including immunotherapy and targeted treatments.
- Novel combination therapies
- Chemoimmunotherapy applications
- Relapse management protocols
Soft Tissue Sarcomas
Their work encompasses comprehensive treatment of rhabdomyosarcoma, focusing on both frontline and relapsed cases. The investigator employs various therapeutic modalities including systemic therapy and radiotherapy approaches.
- Radiation therapy optimization
- Maintenance therapy protocols
- Risk-stratified treatment strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.